Pulmonology

AAAAI 2025. One study found the 2 newer biologics have been prescribed more frequently while the other suggests asthma treatment may not be optimal or even consistent.

AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.

Some hospitals have EDs filled with patients and a number of states are reporting the 2024-2025 version of a COVID-19, flu, and RSV tripledemic.

Topline data announced by Boehringer Ingelheim for the PDE4B inhibitor showed a statistically significant absolute change from baseline in FVC at week 52 vs placebo.

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.

People with chronic diseases like COPD or with immunocompromising conditions continue to have reservations about vaccines against flu, COVID-19, and RSV.

The planned Phase 2 trial in IPF will focus on assessing MTX-463’s safety, pharmacokinetics, and efficacy.

The FDA approved the addition of Guillain-Barré syndrome warnings for Abrysvo and Arexvy, citing postmarketing data suggesting an increased risk.